Syncona Limited NPV (SYNC)

Sector:

Investment Firms

Index:

FTSE 250

222.00p
   
  • Change Today:
      0.50p
  • 52 Week High: 294.00
  • 52 Week Low: 203.00
  • Currency: UK Pounds
  • Shares Issued: 663.67m
  • Volume: 438,620
  • Market Cap: £1,473.34m
  • RiskGrade: 291

Syncona launches cell-therapy company to combat organ rejection

By Duncan Ferris

Date: Monday 20 May 2019

LONDON (ShareCast) - (Sharecast News) - Syncona confirmed on Monday that it has founded a new cell-therapy treatment company, pitching in with £34.0m to fund the new venture in exchange for a 69.3% stake.
Newly formed Quell Therapeutics, which has also enjoyed a £1.0m contribution from the UCL Technology Fund, will focus on the prevention of organ rejection in transplant patients through the development of treatments using T regulatory (Treg) cells.

It is the tenth life science company to be founded by FTSE 250-traded Syncona, which identified Treg cells as an area of high interest in late 2017 and began exploring the possibility of founding a company with the potential to be a global leader in the emerging area.

This process resulted in the company gathering six experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases from King\'s College London, UCL, and Hannover Medical School in order to launch Quell.

Elisa Petris, partner of Syncona Investment Management Limited, said: \"Over the last year, we have worked to bring together a group of world-class leaders in their respective fields, developed a strategy for the business and funded the business to enable it to scale and succeed. We look forward to continuing to work in close partnership with them as we build out the company\'s management team and business plan to deliver their goal of becoming the leader in treating conditions of immune dysfunction utilising gene-modified cells.\"

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

SYNC Market Data

Currency UK Pounds
Share Price 222.00p
Change Today 0.50p
% Change 0.23 %
52 Week High 294.00
52 Week Low 203.00
Volume 438,620
Shares Issued 663.67m
Market Cap £1,473.34m
RiskGrade 291

SYNC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
89.91% below the sector average89.91% below the sector average89.91% below the sector average89.91% below the sector average89.91% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
53.68% below the sector average53.68% below the sector average53.68% below the sector average53.68% below the sector average53.68% below the sector average
Income
Market averageMarket averageMarket averageMarket averageMarket average
95.37% below the sector average95.37% below the sector average95.37% below the sector average95.37% below the sector average95.37% below the sector average
Growth
Market averageMarket averageMarket averageMarket averageMarket average
41.32% above the sector average41.32% above the sector average41.32% above the sector average41.32% above the sector average41.32% above the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

SYNC Dividends

  Latest Previous
  Final Final
Ex-Div 20-Jun-19 21-Jun-18
Paid 29-Jul-19 30-Jul-18
Amount 2.30p 2.30p

Trades for 24-Jan-2020

Time Volume / Share Price
16:35 75,714 @ 222.00p
16:29 14 @ 222.00p
16:21 293 @ 223.00p
16:21 683 @ 222.50p
16:07 204 @ 223.00p

Top of Page